Afinitor looks like it will be the centerpiece of NVS’ drug portfolio in the post-Diovan era. This mantle was originally supposed to fbe carried by Galvus and Tekturna, but Galvus never obtained FDA approval and Tekturna to date has been a commercial dud.
Market Data 
Markets 
AI
